Navigation Links
Compound from marine bacteria shows potential as multiple myeloma therapy

An anti-cancer compound derived from bacteria dwelling in ocean-bottom sediments appears in laboratory tests to be a potent killer of drug-resistant multiple myeloma cells, and potentially with less toxicity than current treatments, report Dana-Farber Cancer Institute researchers in the November issue of Cancer Cell.

The experimental compound, NPI-0052, has been found to block or inhibit cancer cells' proteasomes from working effectively. The proteasome work as a cell's "garbage disposal," chewing up and disposing of old, unwanted proteins. With their proteasome jammed, cells die from the backup of damaged proteins.

"Proteasome inhibition is a key therapeutic target and bortezomib (Velcade tm) was the first in a new class of compounds in multiple myeloma. NPI-0052 is a novel proteasome inhibitor with a chemical structure and action that is distinct from bortezomib, and has the promise of being even more effective for patients," says Kenneth Anderson, MD, director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber, and senior author of the report.

The compound will be moved into Phase I clinical trials in early 2006, say officials of Nereus Pharmaceuticals in San Diego, the developer of NPI-0052. The compound will be tested as a single agent and subsequently in combination with other treatments.

Multiple myeloma is a currently incurable cancer of the bone marrow that causes a plunge in the production of vital red and white blood cells. Although relatively rare, it is the second most common type of blood cancer and accounts for 11,000 deaths annually in the United States. Bortezomib, approved by the Food and Drug Administration in 2003 for relapsed myeloma patients and subsequently for patients who have received at least one prior treatment, demonstrated in clinical trials that it extended the time to disease progression and also improved survival.

Though less toxic than conventional chemotherapy, bortezomib does have
'"/>

Source:Dana-Farber Cancer Institute


Page: 1 2 3

Related biology news :

1. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
2. Newly Discovered Compound Blocks Known Cancer-Causing Protein
3. Compounds in plastic packaging act as environmental estrogens altering breast genes
4. Compound might defeat African sleeping sickness, clinical trial beginning this month
5. Compound from Chinese medicine shows promise in head and neck cancer
6. Anti-cancer Compound In Beer Gaining Interest
7. Compound in dairy products targets diabetes
8. Compound eyes, evolutionary ties
9. Sequencing of marine bacterium will help study of cell communication
10. Solutions that reduce death of marine life reeled in by International Smart Gear Competition
11. UN environmental agency steps up battle against marine pollution
Post Your Comments:
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. (NASDAQ: ... its wholly owned subsidiary, 3D-ID LLC, a company engaged ... Battelle for the biometrics technology portion of the recently ... from the Department of the Army. 3D-ID ... developed for government, law enforcement and security agencies. ...
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS ... had a strong showing at AUVSI,s Unmanned 2015 ... representatives of Ohio,s UAS industry met ... abroad from all points along the UAS ecosystem. ... Coalition,s (DDC) Vice President for Aerospace Rich Knoll . ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... electronic system that stimulates the nerve of the diaphragm muscles ... for use in patients with Amyotrophic Lateral Sclerosis (ALS), also ... Diaphragm Pacing System (DPS) will help ALS patients breathe longer ... the surgeon at University Hospitals (UH) Case Medical Center who ...
... Most drug therapy interventions for people with autism have ... Now, University of Missouri researchers are examining the use ... pressure and control heart rate as well as to ... with autism difficulty with normal social skills, language ...
... available in German . , London. The global uptake ... cent more than previously thought. This is the conclusion of an ... atoms in the carbon dioxide of the atmosphere driven by the ... converted faster than expected during the El Nio years, current estimates ...
Cached Biology News:Diaphragm pacing system receives FDA approval for use with ALS patients 2Study finds promising drug treatment for improving language, social function in people with autism 2Productivity of land plants may be greater than previously thought 2Productivity of land plants may be greater than previously thought 3
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... 21, 2015 Patent Offering, The patent’s ... diagnostic or therapeutic imaging within a body lumen (open ... endoscope having a low cost, single-use disposable illumination and ... was October 18, 2013 and the patent approval was ... the physician to customize the lighting and magnification of ...
(Date:5/21/2015)... , May 20, 2015 Research and Markets ... addition of the "2015 Global Survey on ... offering. The primary goal of this ... cytometry instruments and reagents. Key information the survey ... selection of flow cytometers, predominantly used applications for ...
(Date:5/21/2015)... Prussia, PA (PRWEB) May 21, 2015 ... O’Neill has joined the firm as senior statistician and ... 30 years of experience in the management and analysis ... biologics, pharmaceutical and chemical industries. , “We’re delighted to ... longstanding capabilities in data analytics,” said Dr. Philippe Cini, ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Global Survey on Flow Cytometry Adoption Trends 2015 2Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... Acquisition Expected to Add New Drug Products to Aida Pharmaceuticals, ... ... MONICA, Calif., March 27 Aida,Pharmaceuticals, Inc. (OTC Bulletin Board: ... to acquire a controlling interest,in one of the leading microbiology ...
... Pharmasset, Inc.,(Nasdaq: VRUS ), a pharmaceutical company ... treat viral infections, is,pleased to announce the appointment ... the,Board of Directors and the Nominating and Corporate ... the Board of Directors of Sapphire,Therapeutics, a Director ...
... Led by OrbiMed Advisors, World,s Largest Healthcare ... ... a,bio-pharmaceutical company developing Anticalins(R), a novel class of,targeted human protein therapeutics, ... by new investor OrbiMed Advisors LLC, a major global fund dedicated,to ...
Cached Biology Technology:Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the People's Republic of China 2Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the People's Republic of China 3Pharmasset Appoints Herbert J. Conrad as a Director 2Pharmasset Appoints Herbert J. Conrad as a Director 3Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round 2Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round 3Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round 4
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
Sf21 cells derived from Spodoptera frugiperda ovarian cells are recommended for high-level production of recombinant proteins. Higher expression levels of some proteins are seen due to the larger ce...
... universal lysis buffer, PCR mix, DNA polymerase ... l volume PCR reactions. This system can ... positive rod and coccus bacteria, such as ... Aureus, Streptococcus Agalactiae, and etc. With the ...
...
Biology Products: